¿Dermopatía fibrosante nefrogénica o fibrosis sistémica nefrogénica? ¿Qué es lo que sabemos y qué debemos aprender?

Translated title of the contribution: Nephrogenic fibrosing dermopathy or nephrogenic systemic fibrosis? What we know and what we have to learn

L. M. Ortega, G. Contreras, O. Lenz

Research output: Contribution to journalReview article

7 Scopus citations


Nephrogenic systemic fibrosis (NSF) was first recognized as a unique entity in 1997 and subsequently defined in the literature in 2000 as a novel fibrosing disorder occurring in the setting of renal disease. Prevention, early recognition and treatment are essential to limiting its impact. The most important risk factors for developing NSF are chronic or significant acute kidney disease (especially dialysis dependent patients) and the administration of gadolinium (GD3) containing contrast agents, agents that cause NSF by releasing free gadolinium (GD3) into tissues based on their pharmacokinetics. International commissions in drug control and medicinal products recommend to avoid gadolinium based contrast agents in patients with GFR <30ml/minute/1.73m 2. Unfortunately there is lack of universally effective therapy at this time and the literature is based on case reports and small case series. Recommendations to guide the use of gadolinium based contrast agents in patients with underlying kidney disease should be individualized and considered in consultation with the ordering physician, radiologist and nephrologist.

Original languageSpanish
Pages (from-to)109-117
Number of pages9
Issue number2
StatePublished - Jul 24 2009


ASJC Scopus subject areas

  • Nephrology

Cite this